AU2002230888A1 - Methods and compositions to treat conditions associated with neovascularization - Google Patents

Methods and compositions to treat conditions associated with neovascularization

Info

Publication number
AU2002230888A1
AU2002230888A1 AU2002230888A AU3088802A AU2002230888A1 AU 2002230888 A1 AU2002230888 A1 AU 2002230888A1 AU 2002230888 A AU2002230888 A AU 2002230888A AU 3088802 A AU3088802 A AU 3088802A AU 2002230888 A1 AU2002230888 A1 AU 2002230888A1
Authority
AU
Australia
Prior art keywords
neovascularization
compositions
methods
conditions associated
treat conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002230888A
Other languages
English (en)
Inventor
Kin-Ping Wong
Caiyao Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wackvom Ltd
Original Assignee
Wackvom Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wackvom Ltd filed Critical Wackvom Ltd
Publication of AU2002230888A1 publication Critical patent/AU2002230888A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2002230888A 2000-12-15 2001-12-14 Methods and compositions to treat conditions associated with neovascularization Abandoned AU2002230888A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25587600P 2000-12-15 2000-12-15
US60/255,876 2000-12-15
PCT/US2001/048520 WO2002047673A2 (en) 2000-12-15 2001-12-14 Methods and compositions to treat conditions associated with neovascularization

Publications (1)

Publication Number Publication Date
AU2002230888A1 true AU2002230888A1 (en) 2002-06-24

Family

ID=22970220

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002230888A Abandoned AU2002230888A1 (en) 2000-12-15 2001-12-14 Methods and compositions to treat conditions associated with neovascularization

Country Status (7)

Country Link
US (1) US6608107B2 (enrdf_load_stackoverflow)
EP (1) EP1343487A2 (enrdf_load_stackoverflow)
JP (1) JP2005502579A (enrdf_load_stackoverflow)
CN (1) CN100490791C (enrdf_load_stackoverflow)
AU (1) AU2002230888A1 (enrdf_load_stackoverflow)
MY (1) MY134562A (enrdf_load_stackoverflow)
WO (1) WO2002047673A2 (enrdf_load_stackoverflow)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385936A (en) 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US7427689B2 (en) * 2000-07-28 2008-09-23 Georgetown University ErbB-2 selective small molecule kinase inhibitors
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US7354928B2 (en) 2001-11-01 2008-04-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at Bcl-2
CN100413493C (zh) * 2003-06-11 2008-08-27 中国科学院动物研究所 棉酚及其衍生物在制备治疗骨髓瘤药物中的应用
EP1653943B3 (en) * 2003-06-25 2008-07-30 The Burnham Institute Catechol derivatives for the treatment of cancer
US20050147631A1 (en) * 2004-01-07 2005-07-07 Goldstein Mindy S. Cosmetic composition and method for retarding hair growth
EP1732529A4 (en) 2004-03-25 2009-02-25 Univ Michigan GOSSYPOL KOKRISTALLE AND ITS USE
US20110091552A1 (en) * 2007-08-31 2011-04-21 Mccaffrey Tim Use of Bcl Inhibitors for the Treatment of Scarring Caused By Cutaneous Wounds, Burns and Abrasions
WO2009045410A1 (en) * 2007-10-01 2009-04-09 Ascenta Therapeutics, Inc. Process for preparing r-gossypol l-phenylalaninol dienamine
SG177327A1 (en) 2009-06-22 2012-02-28 Cabot Microelectronics Corp Cmp compositions and methods for suppressing polysilicon removal rates
EP2460837B1 (en) 2009-07-29 2018-03-21 Teijin Chemicals, Ltd. Polycarbonate/polydiorganosiloxane copolymer
CN101810577B (zh) * 2010-05-06 2011-09-07 山东大学 治疗肿瘤的棉酚静脉注射脂肪乳剂
CN103467538B (zh) * 2012-05-29 2015-08-19 武汉大学 具有抗艾滋病毒活性的棉酚衍生物及其制备方法
US9750761B2 (en) * 2014-05-21 2017-09-05 University Of Rochester LDH inhibitors as treatment for fibrosis and fibrotic-related disorders
EP3950060A4 (en) * 2019-04-04 2023-04-19 Nissan Chemical Corporation Composition for promoting secretion of extracellular vesicles
CN110559449B (zh) * 2019-10-22 2022-09-02 长治医学院 一种聚棉酚前药胶束及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260327A (en) * 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
US5026726A (en) * 1989-12-11 1991-06-25 The University Of New Mexico Gossylic iminolactones and gossylic lactones and their anti-viral activities
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US5936120A (en) * 1997-12-10 1999-08-10 University Of New Mexico Deoxygossylic compounds
US5780675A (en) * 1995-04-28 1998-07-14 The University Of New Mexico Deoxygossylic compounds
CN1078462C (zh) * 1997-07-09 2002-01-30 辛国芳 棉酚和/或其衍生物作为有效成分在制备用于治疗前列腺炎的栓剂中的应用

Also Published As

Publication number Publication date
WO2002047673A2 (en) 2002-06-20
JP2005502579A (ja) 2005-01-27
US20020137801A1 (en) 2002-09-26
CN100490791C (zh) 2009-05-27
EP1343487A2 (en) 2003-09-17
WO2002047673A3 (en) 2003-01-03
US6608107B2 (en) 2003-08-19
CN1529590A (zh) 2004-09-15
MY134562A (en) 2007-12-31

Similar Documents

Publication Publication Date Title
AU2778801A (en) Antisense compositions and methods
AU2002230888A1 (en) Methods and compositions to treat conditions associated with neovascularization
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2001239947A1 (en) Methods and compositions for regulating adipocytes
AUPQ419099A0 (en) Novel compositions and methods
AU2001250875A1 (en) Anti-microbial and immunostimulating composition
AU2001268659A1 (en) Water treatment compositions
AU2002210575A1 (en) Novel medicament compositions based on anticholinergics and corticosteroids
GB9920678D0 (en) Sanitising compositions and methods
AU2002229616A1 (en) Improvements in and relating to the distribution of content
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AU2001229597A1 (en) Compositions and methods to treat neurodegenerative disorders
AU2002241911A1 (en) Methods to treat autoimmune and inflammatory conditions
AU2002365936A1 (en) Compositions and methods to treat gastrointestinal disorders
AU2002239739A1 (en) Compositions, methods and kits relating to remodelin
AU2001247471A1 (en) Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones
AU2003263988A1 (en) Methods and compositions to treat conditions associated with neovascularization
AU2001233086A1 (en) Ceramidase compositions and methods based thereon
AU2002366809A1 (en) Syn3 compositions and methods
AU2001266648A1 (en) Kits and methods for optimizing the efficacy of chondroprotective compositions
AU2001261317A1 (en) Immunostimulant compositions and associated methods
AU2001234685A1 (en) Methods and compositions for enhancing formyltetrahydropteroylpolyglutamate in plants
AU2001236001A1 (en) Immune enhancement compositions and use thereof
AU2001261738A1 (en) Compositions and methods for promoting immunosuppression
AUPR175600A0 (en) Novel treatment methods and compositions